Institute for Biomedical Sciences News

Arin Dorsey (B.I.S. ’24) juggled many duties during her time at Georgia State, from working full time as a nursing assistant to doing biomedical research and volunteering for worthy causes.

Muhammed Hasan Mumen (B.I.S. ’22), a Biomedical Science and Enterprise graduate and now a medical school student, is on his way to becoming a physician who aims to connect with patients and provide excellent care.

Chong Hyun Shin, a research assistant professor in the Institute for Biomedical Sciences at Georgia State University, has received a three-year, $600,000 federal grant to study small molecules targeting obesity-linked diabetes.

Starting antiviral treatment as late as 14 days after infection with SARS-CoV-2 may still be beneficial in hosts with compromised immune systems, according to researchers in the Center for Translational Antiviral Research at Georgia State University’s Institute for Biomedical Sciences.

Certain types of gut bacteria can hinder the efficacy of the rotavirus vaccine, according to researchers in the Institute for Biomedical Sciences at Georgia State University.

The Board of Regents of the University System of Georgia (USG) has appointed and reappointed outstanding faculty to the system’s highest academic rank, the Regents’ Professor.

Nanoparticle vaccines can produce pivotal cellular and mucosal immune responses that enhance vaccine efficacy and broaden protection, according to a study by researchers in the Institute for Biomedical Sciences at Georgia State University.

The appointment of Distinguished University Professor at Georgia State is intended to recognize a sustained and outstanding record in scholarship and instruction, and to provide the impetus for continuing high achievement.

Kripa Sharma (B.I.S. ’23) hopes to one day increase access to dental care and bridge healthcare disparities.

After earning both a bachelor’s and master’s degree at Georgia State, Dylan McCouch (B.S. ’16, M.I.S. ’18) reached higher to earn a doctor’s degree and now works as a physical therapist in the Atlanta area.

Novel tools from research on antivirals at Georgia State University are now making their way to the marketplace.

Sarah Santiago (B.I.S. ’24) has set her sights on becoming a dentist, with hopes of one day opening her own dental practice or leading the Division of Oral Health at the Centers for Disease Control and Prevention.

Through the support of an anonymous donor, the Institute for Biomedical Sciences at Georgia State University has awarded its newly established Yes, I Can Scholarship to 12 outstanding undergraduate students.

Sandhya Padmanabhan (Ph.D. ’24), a graduate of the Translational Biomedical Sciences program, was inspired to earn a Ph.D. to fulfill her father’s dream. Now, she wants to make a difference in the study of infectious diseases.

Angel Ferary (B.I.S. ’24) juggled many responsibilities at Georgia State, including playing on the beach volleyball team, coaching part time and completing an internship at the Georgia Bureau of Investigation.

A new student organization in the Institute for Biomedical Sciences at Georgia State has been awarded the Royal Flame Award for Outstanding Large-Scale Campus Program on the Atlanta Campus.

Two Georgia State students were recognized for their passion for research with the prestigious Goldwater Scholarship. Sara Guedez Suarez and Rashawn Thomas are among 438 undergraduates from across the nation who received this award.

Infection with a measles-like virus causes catastrophic lung failure in ferrets previously infected with influenza virus or respiratory syncytial virus, according to a study by researchers in the Center for Translational Antiviral Research at Georgia State University.

Influenza A viruses with induced resistance to a new candidate antiviral drug were found to be impaired in cell culture and weakened in animals, according to a study by researchers in the Center for Translational Antiviral Research at Georgia State University.

The composition of microbiota found in the gut influences how susceptible mice are to respiratory virus infections and the severity of these infections, according to researchers from the Center for Translational Antiviral Research in the Institute for Biomedical Sciences.

Georgia State’s 40 Under 40 program annually celebrates the most influential and accomplished Georgia State graduates who embody the values of the university.

Jannatul Ruhan Raha's research is focused on an intranasal vaccine that improves protection against the flu.

Kotryna Diktonaite (M.I.S. ’23) wanted to pursue a career that focused on both research and data, so she completed an online certification in data analysis in addition to her regular coursework.

After landing a co-op at Moderna, Rika Semalty (M.I.S. ’23) knew she wanted to pursue a career as a research scientist.

Liya Moges (B.I.S. ’23) is one step closer to fulfilling her lifelong dream of becoming a physician and opening her own medical practice.

Two leading researchers in the Institute for Biomedical Sciences at Georgia State have been ranked in the top 1 percent worldwide by citations for their field and publication year in the Web of Science database.

An oral lipid nanoparticle drug prevents tumor development in mice, suggesting this is a promising drug formulation for preventing colitis-associated cancer, according to a study led by researchers in the Institute for Biomedical Sciences at Georgia State University.

Sara Clasen, a postdoctoral fellow in the Institute for Biomedical Sciences, is the grand prize winner of the prestigious 2023 NOSTER & Science Microbiome Prize, which rewards innovative research by young investigators.

Denning, also a Distinguished University Professor, has led the university’s research community to historic growth and new funding records for the past three years.

After earning a science degree and having a variety of jobs in different industries for 10 years, Jennifer Rangelov (M.I.S. ’22) returned to school to take her career to the next level.

Two oral drugs, molnupiravir and paxlovid (nirmatrelvir/ritonavir), provide equivalent therapeutic benefit in preventing severe COVID-19 in animal models, but only molnupiravir efficiently blocked SARS-CoV-2 transmission when administered at a human effect size-equivalent dose, according to a study led by researchers at Georgia State University’s Center for Translational Antiviral Research in collaboration with the Emory University Institute for Drug Development.

Carolin Lieber, a Ph.D. student in the Translational Biomedical Sciences program and the recipient of the prestigious Rosalind Franklin Society Award in Science, strives to be a role model.

The grants support early stage research initiatives by faculty members across the university.

The RFS Award in Science celebrates the work of women and minorities in the life sciences.

The grant from the National Institutes of Health’s National Heart, Lung, and Blood Institute will be used to explore the role of diabetes-induced alteration of gut microbiota.

This is the second year of the radon workshop at Perimeter College, which is designed to promote more hand-on science projects for middle and high school teachers to bring to their students, while also teaching about the effects of chemicals and radon in the environment through experiments and testing.

Khayla McClinton (M.I.S. ’21) has a thriving research career as a clinical trials associate at Seattle-based Sana Biotechnology and gives back to Georgia State students through her mentoring program.

A novel type of protein nanoparticle vaccine formulation containing influenza proteins and adjuvant to boost immune responses has provided complete protection against influenza viral challenges, according to a new study published by researchers in the Institute for Biomedical Sciences at Georgia State University.

After facing many health challenges in his own family and watching his relatives care for other patients, Christopher Nava (B.I.S. ’23) dreams of becoming a physician assistant.

Passionate about business and healthcare, Annabel Winn (B.I.S. ’23) has set her sights on a career in supply chain management and logistics in the healthcare field.

Through the support of a generous donor, the Institute for Biomedical Sciences at Georgia State University has established the Yes, I Can Scholarship, and has awarded seven scholarships to outstanding undergraduate students.

Psyllium fiber protects against ulcerative colitis and suppresses inflammation by activating the bile acid nuclear receptor, a mechanism that was previously unrecognized, according to a new study by researchers in the Institute for Biomedical Sciences at Georgia State University.

Georgia State Chemistry Professor Paulos Yohannes is helping to open the door to the power of Ethiopia's medicinal plants.

Amani Mallory (B.I.S. ’16, M.I.S. ’19) is working on the technical side of health care at an Atlanta-based software company, assisting customers involved in clinical research with software implementation and driving user engagement.

Started in 2018, Georgia State’s 40 Under 40 program annually celebrates the most influential and accomplished Georgia State graduates who embody the values of the university.

If a lactating mother consumes a diet lacking dietary fiber, her young offspring will lack microbial diversity in their gut and have low-grade inflammation, making them highly prone to developing obesity, according to a new study in mice by researchers in the Institute for Biomedical Sciences at Georgia State University.

Junsik Sung has wanted to become a scientist since he was 5 years old. His lifelong dream is coming true this fall as he graduates with a Ph.D. in Translational Biomedical Sciences from the Institute for Biomedical Sciences.

With a decade of experience in emergency medical services, Miranda Baras (M.I.S. ’22) is pursuing a new career focused on biotechnology and medical devices and has even launched her own startup medical device company.

Graduating a semester early from the Biomedical Science and Enterprise program and Honors College, Shivani Patel already has a full-time position with a multinational company.

As the COVID-19 pandemic persists, scientists around the world and at Georgia State are working tirelessly to outsmart new variants and plan for the next virus with pandemic potential.

After completing a Ph.D. in Translational Biomedical Sciences, Stephen Maurakis is on his way to achieving his goal of becoming a senior scientist focused on fighting serious pathogens.

Dr. Cynthia Nau Cornelissen, Distinguished University Professor and director of the Center for Translational Immunology in the Institute for Biomedical Sciences at Georgia State, has received a five-year, $4.9 million federal grant to study ways to block the bacterial pathogen Neisseria gonorrhoeae from causing gonorrhea, a common sexually transmitted infection.

Gonorrhea, which affects more than 80 million people worldwide each year, is a global threat to public health because of the increasing incidence of antimicrobial drug resistance, rising treatment costs and lack of a protective vaccine.

With a Ph.D. in Translational Biomedical Sciences under her belt, Latika Luthra is ready to start her career focused on intellectual property and research commercialization with plans to one day become a patent attorney.

Jennifer Kusovschi (B.S. ’17, M.I.S. ’22) earned a master’s degree in Biomedical Science and Enterprise while participating full time in a research fellowship at the CDC and directing a choir for young women at her church.

The researchers designed a single, universal influenza vaccine candidate that protects against diverse variants of both influenza A and B viruses in mice.

Oral delivery of lipid nanoparticles that target the colon with nucleic acids is a novel therapeutic strategy for treating ulcerative colitis, according to a new study by researchers in the Institute for Biomedical Sciences at Georgia State University.

The Georgia State University Alumni Association has named three new members to its Board of Directors and 18 new members to the Young Alumni Council board.

The Board of Regents of the University System of Georgia has appointed and reappointed seven faculty at Georgia State with the designation of Regents’ Professor, the highest professorial rank within the state’s system of public colleges and universities.

SARS-CoV-2 variants of concern and the biological sex of patients affect the efficacy of molnupiravir, the first orally available drug approved for outpatient use against COVID-19, according to a new study led by researchers at Georgia State University.

A new universal flu vaccine protects against influenza B viruses, offering broad defense against different strains and improved immune protection, according to a new study by researchers in the Institute for Biomedical Sciences at Georgia State University.

A new universal flu vaccine constructed with key parts of the influenza virus offers broad cross protection against different strains and subtypes of influenza A viruses, according to a new study by researchers in the Institute for Biomedical Sciences.

A new oral treatment for ulcerative colitis that focuses on reducing inflammation in gut microbiota has been developed by researchers in the Institute for Biomedical Sciences at Georgia State University, according to a new study.

An oral antiviral drug that targets a key part of the respiratory syncytial virus (RSV) polymerase has been identified, a finding that could provide an effective treatment against RSV disease, according to researchers in the Center for Translational Antiviral Research at Georgia State University.

The new university initiative establishes interdisciplinary research hubs to address some of society’s most pressing issues, including pandemic preparedness, climate solutions, crime victim protection, equity and access, and public health.

Scientists from Georgia State are working to build a pipeline of antiviral drugs targeting COVID-19 and other viral threats with pandemic potential.

A nanoparticle vaccine that combines two proteins that induce immune responses against SARS-CoV-2, the virus that has caused the global pandemic, has the potential to be developed into broader and safe SARS-CoV-2 vaccines, according to researchers in the Institute for Biomedical Sciences at Georgia State University.

The new center at Emory and Georgia State is led and co-founded by researchers with a history of collaborating on successful antiviral drugs, including molnupiravir, which was one of the world’s first antiviral pills approved for use against SARS-CoV-2.

Passionate about health, Kacey King (B.I.S. ’22) is an aspiring physician who hopes to inspire others to stay in shape.

Georgia State researchers are teaming up with industry in new ways to help bring their innovative breakthroughs to the marketplace.

After witnessing the wave of misinformation during the pandemic, Jade Christman (B.I.S. ’22) wants to make science more accessible.

With experience as a bilingual medical scribe, Gem Johnson plans to travel to South America after graduation to treat residents of rural Peru.

Drugs for inflammatory bowel disease are ineffective and have serious side effects. Professor Didier Merlin is developing a better treatment approach using nanotechnology.

Two biomedical science innovations from Georgia State University have been chosen to compete in STAT Madness 2022, a contest to select the top innovation or discovery in biomedical science from last year.

An influenza vaccine constructed with nanoparticles that enhance immune response offers strong protection against different influenza virus strains, according to researchers in the Institute for Biomedical Sciences at Georgia State University.

The 40 Under 40 program honors, recognizes and celebrates the most influential and impactful Georgia State graduates under the age of 40 who embody the values of the university.

A new course offered in the Biomedical Enterprise master’s program in the Institute for Biomedical Sciences teaches students about scientific commercialization.

Dr. Didier Merlin, a Distinguished University Professor in the Institute for Biomedical Sciences at Georgia State University and a Senior Research Career Scientist at VA Medical Center, is available to discuss his research on developing new drug delivery platforms to treat intestinal bowel disease (IBD) and colorectal cancer using nanotechnology approaches.

Grace Bendinger (B.S.N. ’11, M.I.S. ’21) was looking for a way to improve patient care on a broader scale. With the Master of Interdisciplinary Studies in Biomedical Enterprise she’ll receive this fall from the Institute for Biomedical Sciences at Georgia State, she’ll be doing just that.

In a study published online on Dec. 2 in Science, researchers in the Institute for Biomedical Sciences at Georgia State University report a new candidate that has potent antiviral activity against SARS-CoV-2 when administered orally once-daily.

New clinical research indicates that a widely used food additive, carboxymethylcellulose, alters the intestinal environment of healthy persons, perturbing levels of beneficial bacteria and nutrients. These findings, published in Gastroenterology, demonstrate the need for further study of the long-term impacts of this food additive on health.

Zahra Alghoul, a fall 2020 graduate of the Biomedical Enterprise master’s degree program in the Institute for Biomedical Sciences, already had a Ph.D. in analytical chemistry and a job teaching college chemistry courses, but she wanted to learn more about the business of science.

Dr. Lanying Du, a professor in the Institute for Biomedical Sciences at Georgia State University, has been ranked in the top 0.1 percent of scientists in the world for having multiple highly cited papers based on field and publication year in the Web of Science citation index.

To better reach outpatients early after a COVID-19, infection, Gilead Sciences Inc. has partnered with researchers in Georgia State University’s Center for Translational Antiviral Research to test a modified version of remdesivir that can be taken orally.

A new research center led by Richard Plemper in the Institute for Biomedical Sciences will develop critical antiviral drugs to meet the challenge of existing and newly evolving threats, such as coronaviruses.

Professor Christopher Basler has spent his career stalking Ebola, and recently he hit upon a surprising discovery that could suggest new ways to treat the deadly infection.

Caroline Williams earned her Ph.D. in Translational Biomedical Sciences by embarking upon studies of two newly emerging viruses, SARS-CoV-2, the virus that causes COVID-19, and Mengla virus, a newly identified filovirus.

Georgia State University was highlighted in a press briefing Oct. 6 by the White House COVID-19 response team, which recognized the university’s contribution to groundbreaking research that led to the development of molnupiravir.

A new antiviral drug tested in the Institute for Biomedical Sciences at Georgia State against influenza virus and SARS-CoV-2 has been recommended for emergency use authorization to treat COVID-19 in the United States by pharmaceutical companies that completed a Phase 3 clinical trial and achieved promising results.

Khadijah Ameen, Tyler McCoy Gay and Keiwana Glover were recently named participants in the prestigious Health Policy Research Scholars program, which equips doctoral students with the skills to influence public policy and create a culture of health.

Khayla McClinton, a master’s student in the Institute for Biomedical Sciences, spent her summer at the Chan Zuckerberg Biohub in San Francisco, participating in projects related to data science, biomedical research and biomedical engineering.

Michal Kuczma, a research assistant professor in the Institute for Biomedical Sciences, has received a Career Development Award from the Crohn’s and Colitis Foundation to study environmental influences on gut microbiota, immunity and inflammation.

Professor Christopher Basler has received two grants from the National Institutes of Health to study two coronaviruses that cause human disease: Middle East respiratory syndrome (MERS) coronavirus and SARS-CoV-2.

The Center for Translational Antiviral Research has been established in the Institute for Biomedical Sciences at Georgia State University to fill the gap for developing affordable, much-needed antiviral drugs that will reduce severe viral diseases and meet the threats imposed by existing and newly evolving viruses.

Scientists in the Institute for Biomedical Sciences have shed light on how cells can slow replication of the Ebola virus, preventing infection. “We hope these findings will enable us to develop new ways to prevent or treat Ebola.”

Compounds targeting two key enzymes are potent inhibitors of SARS-CoV-2, the virus that causes COVID-19, according to a study led by the Institute for Biomedical Sciences at Georgia State.

Dr. Sang-Moo Kang, professor in the Institute for Biomedical Sciences at Georgia State University, has received a five-year, $2.7 million federal grant to study seasonal and universal vaccination in elderly populations with pre-existing immunity to influenza viruses.

Khayla McClinton, a master’s student in the Institute for Biomedical Sciences, wants to close the health access gap and bring the voice of underrepresented communities to conversations about research, discoveries and prevention.

Although Tamariya Hall had a hectic schedule between her classes and fulfilling the prerequisites for dental school, she still made time to volunteer for charitable causes and stand up for social justice issues during her education at Georgia State.

An aspiring doctor, Kristina Andrade wanted to gain valuable, practical experience in the medical field during her undergraduate studies, so she secured a job as a medical assistant at a women’s health care facility in the metro Atlanta area and also traveled abroad to Honduras to help set up medical clinics.

An influenza vaccine that is made of nanoparticles and administered through the nose enhances the body’s immune response to influenza virus infection and offers broad protection against different viral strains, according to researchers in the Institute for Biomedical Sciences at Georgia State University.

Processed diets, which are low in fiber, may initially reduce the incidence of foodborne infectious diseases such as E. coli infections, but might also increase the incidence of diseases characterized by low-grade chronic infection and inflammation such as diabetes, according to researchers in the Institute for Biomedical Sciences.

Dr. Jian-Dong Li, professor and director of the Institute for Biomedical Sciences at Georgia State University, has received a five-year, $2.3 million federal grant to study how overactive inflammatory response is caused in infectious diseases and to further develop novel anti-inflammatory therapeutics.

Viruses have an amazing capacity to mutate. But what if we could turn that against them? Richard Plemper, professor in the Institute for Biomedical Sciences, is working to exploit this rapid evolution.

Gem Johnson has continued her cardiovascular research during the pandemic, even though she hasn’t been able to enter the lab.

Dr. Andrew Gewirtz, a professor in the Institute for Biomedical Sciences at Georgia State University, has received a four-year federal grant just over $2 million to study how inflammation and altered gut microbiota, the microorganisms living in the intestine, influence the development of a group of diseases referred to as metabolic syndrome.

Treatment of SARS-CoV-2 infection with a new antiviral drug, MK-4482/EIDD-2801 or Molnupiravir, completely suppresses virus transmission within 24 hours, researchers in the Institute for Biomedical Sciences at Georgia State University have discovered.

Using an innovative strategy he developed against influenza, professor Baozhong Wang is working on a universal vaccine to protect against all coronaviruses.

There are common vulnerabilities among three lethal coronaviruses, SARS-CoV-2, SARS-CoV-1 and MERS-CoV, such as frequently hijacked cellular pathways, that could lead to promising targets for broad coronavirus inhibition, according to a study by an international research team that includes scientists from the Institute for Biomedical Sciences at Georgia State University.

Dr. Timothy Denning, associate director of the Institute for Biomedical Sciences at Georgia State University, has been named the university’s vice president for research and economic development.

A combination of two substances secreted by the immune system can cure and prevent rotavirus infection, as well as potentially treat other viral infections that target epithelial cells.

Dr. Leszek Ignatowicz, a professor in the Institute for Biomedical Sciences at Georgia State, will study how changes in the microorganisms in the gut, referred to as intestinal microbiota, cause the immune system to decline as organisms get older.

Christopher Basler, professor and director of the Center for Microbial Pathogenesis in the Institute for Biomedical Sciences at Georgia State University, has received a $100,000 COVID-19 Fast Grant to study enzymes that are critical for the replication of SARS-CoV-2, the virus that causes COVID-19.

Sudeep Lama, a master’s degree student in the Institute for Biomedical Sciences, spent his summer working with an international medical device company to market a new diagnostic tool that will soon be available to help epilepsy patients.

Dr. Christopher Basler, professor and director of the Center for Microbial Pathogenesis in the Institute for Biomedical Sciences at Georgia State University, has received a five-year, $2.94 million federal grant to study unique features of Ebola and Marburg viruses that control how the virus family expresses its genes and escapes immune responses.

A new antiviral drug that is effective against a broad range of human pathogens in the paramyxovirus family, such as the human parainfluenzaviruses and measles virus, has been discovered by researchers in the Institute for Biomedical Sciences at Georgia State University.

Dr. Richard Plemper, Distinguished University Professor in the Institute for Biomedical Sciences, has been awarded a five-year, $3.65 million grant from the National Institutes of Health to develop antiviral therapeutics for the treatment of respiratory syncytial virus (RSV) infections.

Georgia State University and Augusta University will provide grants totaling nearly $200,000 to support four research collaborations among faculty from both institutions.

A professor and director of the Center for Microbial Pathogenesis at Georgia State, Chris Basler is studying how the novel coronavirus interacts with the cell it infects.

Detailed methods on how to perform research on SARS-CoV-2, the virus that causes COVID-19, including procedures that effectively inactivate the virus to enable safe study of infected cells have been identified by virologists in the Institute for Biomedical Sciences at Georgia State University.

Dr. Leszek Ignatowicz, a professor in the Institute for Biomedical Sciences at Georgia State University, has received a five-year, $1.95 million federal grant to study what causes autoimmunity in the human body.

Dr. Timothy Denning, associate director of the Institute for Biomedical Sciences at Georgia State University, has been awarded the 2020 Distinguished Alumnus Award from the University of Texas Medical Branch’s Graduate School of Biomedical Sciences (GSBS).

Foods, such as French fries, cheese, cookies, soda, and sports and energy drinks, are commonly found in the diets of United States adults with inflammatory bowel disease, according to a new study by researchers in the Institute for Biomedical Sciences at Georgia State University.

Georgia State researchers have measured antibodies to SARS-CoV-2, the virus that causes the disease COVID-19, in self-collected blood samples from Metro Atlanta residents.

What causes the body to attack itself? Professor Leszek Ignatowicz is challenging scientists’ understanding of how these conditions take root.

Georgia State scientists are joining the race to unravel how the new coronavirus operates — and find effective treatments.

A multidisciplinary team of researchers in the Institute for Biomedical Sciences is combining their expertise to develop therapeutics and vaccines to fight COVID-19.

Georgia State scientists are joining the race to unravel how the new coronavirus operates — and find effective treatments.

Dr. Tim Denning, professor and associate director of the Institute for Biomedical Sciences at Georgia State University, has received a four-year, $1.67 million federal grant to study how an immunological pathway influences inflammatory signaling in the intestine that can lead to chronic human diseases such as inflammatory bowel disease.

A novel nanoparticle vaccine that combines two major influenza proteins is effective in providing broad, long-lasting protection against influenza virus in mice, showing promise as a universal flu vaccine, according to a study by the Institute for Biomedical Sciences at Georgia State University.

Targeted immunization against bacterial flagellin, a protein that forms the appendage that enables bacterial mobility, can beneficially alter the intestinal microbiota, decreasing the bacteria’s ability to cause inflammation and thus protecting against an array of chronic inflammatory diseases, according to a new study by the Institute for Biomedical Sciences and the Neuroscience Institute at Georgia State University.

The deadly childhood disease known as rotavirus produces a staggering annual death toll, but Georgia State researchers have just discovered a way to fight it — with bacteria.

Professor Sang-Moo Kang may have found a way to make a safe vaccine for RSV, an infection that hospitalizes more than 50,000 infants every year.

Biomedical sciences professor Cynthia Nau Cornelissen on the rising threat of antibiotic-resistant gonorrhea and her work to develop the world’s first vaccine against the superbug.

A new antiviral drug that induces mutations in the genetic material of influenza virus is highly effective in treating influenza infection in animals and human airway tissue and could be a groundbreaking advance in influenza therapy, according to a study by the Institute for Biomedical Sciences at Georgia State University.

The presence of specific microbiota, or microorganisms that live in the digestive tract, can prevent and cure rotavirus infection, which is the leading cause of severe, life-threatening diarrhea in children worldwide, according to a new study by the Institute for Biomedical Sciences at Georgia State University.

Creating mutations in a key Ebola virus protein that helps the deadly virus escape from the body’s defenses can make the virus unable to produce sickness and activate protective immunity in the infected host, according to a study by the Institute for Biomedical Sciences at Georgia State University.

Targeting specific areas of the measles virus polymerase, a protein complex that copies the viral genome, can effectively fight the measles virus and be used as an approach to developing new antiviral drugs to treat the serious infectious disease, according to a study by the Institute for Biomedical Sciences at Georgia State University published in PLoS Pathogens.

Blocking the ability of the bacterial pathogen that causes gonorrhea to uptake the mineral zinc can stop infection by this widespread sexually transmitted infection, according to a study by the Institute for Biomedical Sciences at Georgia State University.

A new review book is designed to make studying easier for students in medical school, graduate microbiology programs or undergraduate pre-med programs and individuals preparing for the United States Medical Licensing Examination (USMLE).

Influenza remains a major public health risk, and Dr. Baozhong Wang, associate professor in Georgia State University’s Institute for Biomedical Sciences, has received a five-year, $3.26 million federal grant to combat this threat by developing a universal vaccine that offers more protection against influenza than seasonal vaccines.

Small molecules found in fecal matter could provide clues to the early inflammation found in chronic gut conditions, such as inflammatory bowel disease (IBD), and serve as new biomarkers for diagnosis, according to a study led by the Institute for Biomedical Sciences at Georgia State University.

A unique adjuvant, a substance that enhances the body’s immune response to toxins and foreign matter, can prevent vaccine-enhanced respiratory disease, a sickness that has posed a major hurdle in vaccine development for respiratory syncytial virus (RSV), according to a study led by the Institute for Biomedical Sciences at Georgia State University.

Dr. Cynthia Nau Cornelissen, a leading researcher in the study of infectious diseases, including sexually transmitted infections (STIs), has been named director of the Center for Translational Immunology in the Institute for Biomedical Sciences at Georgia State University.

Your body is much more than just flesh and bones. It’s a complex ecosystem teeming with trillions of microorganisms, which — as Georgia State scientists are finding — may be the key to understanding and treating all kinds of disease.

Asia Johnson, an ultramarathon runner and second year Ph.D. student at the Institute for Biomedical Sciences, is racing toward her mission to improve human health.

With flu vaccines often unreliable and many antiviral drugs no longer effective, a Georgia State professor has developed a new way to fight the ever-evolving, omnipresent threat of the flu — by tricking it.

Exposure to microbiota, or microorganisms such as bacteria, in the early stages of life plays a crucial role in establishing optimal conditions in the intestine that inhibit the development of colon cancer in adulthood, according to a study led by Georgia State University.

Dr. Richard Plemper, a professor in Georgia State University’s Institute for Biomedical Sciences (IBMS), has received a five-year, $5 million federal grant to develop an antiviral drug to treat influenza virus infections.

Georgia State University is part of a national group of leading innovative institutions that has received a $2.4 million grant from the Strada Education Network to redesign the college-to-career pathway.

Dr. Baozhong Wang, associate professor in Georgia State University’s Institute for Biomedical Sciences, has received a five-year, $3.86 million federal grant to develop a universal flu vaccine using a microneedle patch that will protect against any strain of the influenza virus.

Dr. Jun Zou, a research assistant professor in the Institute for Biomedical Sciences at Georgia State University, has received a four-year, $552,000 grant to study how dietary fiber can protect against diabetes and other disorders associated with metabolic syndrome.

Food additives known as dietary emulsifiers, commonly found in processed foods to improve texture and extend shelf life, may adversely affect anxiety-related and social behaviors in mice, Georgia State researchers have found.

A new semester brings fresh opportunities to achieve academic success. Georgia State is excited to welcome back all of our new and returning students for the spring 2019 semester.

Skin vaccination using a microneedle patch that contains the inactivated respiratory syncytial virus (RSV) and a compound that stimulates immune responses to the virus has been found to enhance protection against this serious disease and reduce inflammation in the body after exposure to the virus, according to a study led by Georgia State University.

Several new connections have been discovered between the proteins of the Ebola virus and human host cells, a finding that provides insight on ways to prevent the deadly Ebola virus from reproducing and could lead to novel ways to fight these lethal viral infections, according to a study led by Georgia State University, the University of California, San Francisco, and the Gladstone Institutes.

Medical problems nearly prevented her from earning a college degree. Now Devin McCoy plans to use her own experiences to help pharmaceutical companies better educate patients.

Respiratory syncytial virus sends thousands to the hospital every year and can be fatal for the very young and old — but there is no treatment. Professor Richard Plemper is working to change that.

Adding highly refined fiber to processed foods could have negative effects on human health, such as promoting liver cancer, according to a new study by researchers at Georgia State University and the University of Toledo.

Researchers have identified how a viral protein, which plays a major role in causing deadly Nipah and Hendra virus infections, targets a critical function in human cells to suppress immune responses and promote fatal disease.

Georgia State University is ranked the second most innovative university in the nation and second in the country for its commitment to undergraduate teaching in the 2019 Best Colleges edition of U.S. News & World Report magazine.

Georgia State University has received a five-year, $2.2 million grant to develop combination therapies for respiratory syncytial virus, or RSV, and related respiratory viruses.

A new, double-layered nanoparticle vaccine made with peptides has been found to effectively protect mice against influenza A virus, according to a study led by Georgia State University.

A gene from the deadly Ebola virus that allows the virus to escape from the human immune system has been identified in the genome of a group of bats that is found worldwide, including North America. The gene appears to have been stolen from the virus by the bats and adapted to regulate their own immune response, according to a recent study led by Georgia State University.

Advac, LLC, a vaccine research company founded by Sang-Moo Kang, a professor in the Institute for Biomedical Sciences at Georgia State University, has received $225,000 from the National Institutes of Health to develop a safer, more effective vaccine for human respiratory syncytial virus (RSV).

Dr. Christopher Basler, a professor in the Institute for Biomedical Sciences at Georgia State University, director of the university’s Center for Microbial Pathogenesis and a Georgia Research Alliance Eminent Scholar in Microbial Pathogenesis, has received a two-year, $419,100 federal grant to study a virus similar to Ebola virus that causes disease in animals but not in humans.

Inflammation is an important weapon in your immune system's arsenal, but too much of it can hurt rather than heal. Across campus, Georgia State scientists are tackling the silent, simmering menace of chronic inflammation. 

A new group of proteins called cytokines, critical for antimicrobial activity and repairing the damaged intestinal tissue found in inflammatory bowel disease (IBD), has been discovered by researchers in a study led by Georgia State University.

An organic chemical compound shows effective antiviral activity against Ebola virus and several other viruses, according to a study led by Georgia State University.

Georgia State scientists have identified a chemical compound that may work against the lethal Ebola virus.

Researchers have developed a universal vaccine to combat influenza A viruses that produces long-lasting immunity in mice and protects them against the limitations of seasonal flu vaccines, according to a study led by Georgia State University.

Consumption of dietary fiber can prevent obesity, metabolic syndrome and adverse changes in the intestine by promoting growth of “good” bacteria in the colon, according to a study led by Georgia State University.

Lactic acid bacteria, commonly used as probiotics to improve digestive health, can offer protection against different subtypes of influenza A virus, according to a study led by Georgia State University.

ATLANTA—Specific immune cells have the ability to produce a healing factor that can promote wound repair in the intestine, a finding that could lead to new, potential therapeutic treatments for inflammatory bowel disease (IBD), according to a new research study.

ATLANTA—Georgia State's Institute for Biomedical Sciences (IBMS) has welcomed its first class of nine Ph.D. students enrolled in an innovative and interdisciplinary program meant to cultivate the next generation of leaders in the biomedical sector.